ClinicalTrials.gg
RecruitingNCT02900521BRESTUpdated May 26, 2023

Population-based Brest Stroke Registry

An observational study in Cerebral (CVAs), Ischemic Cerebrovascular Accident and Stroke, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2023-05-26.

Sponsored by University Hospital, Brest · Observational

How we know

From the registry’s dates

  • Started Jan 2008; still recruiting 18 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15,000
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Ischemic Stroke with a site in France — 56 open to participants now, 61 under way, 10 of them phase 3. Ischemic Stroke · France.

Planned enrollment
3rd of 55
15,000 · median 250
Started
2008
with 3 others
Observational
55 of 164
20 open now
Primary completion
2016-08
later than 0 of 60 live
Registered
46th of 164
by date

Among the 164 studies in Ischemic Stroke with a site in France, this one is the 3rd largest by planned enrollment of the 55 observational ones that give a count, is one of 4 that started in 2008, is one of 55 observational ones, reaches primary completion later than 0 of the 60 other live ones, and was the 46th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

56 of the 164 studies in Ischemic Stroke with a site in France are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Ischemic Stroke with a site in France, or all of them as a file.
02

Study summary

The registry is the main objective exhaustive list of cases validated stroke brain on a geographical area defined to calculate an incidence.

Read the detailed description

The main objective of Brest Stroke Registry is to regroup all confirmed cases of stroke over a defined geographical zone in order to calculate an incidence.

There are three prospective medium-term goals:

  • In respect with public health epidemiology:
  1. To obtain incidence data and evaluate the regional and international divergences
  2. To obtain the mortality data in short and long term. Since the onset of the registry, it has been implemented a study on the mortality of stroke patients of Brest Registry. This study has been realized independently for both types of stroke, i.e. ischemic and hemorrhagic, with different caused mortality. This mortality was studied at medium-term (≤ 28 days) as well as at long-term (> 28 days). There will be a collaboration project between Public Health Surveillance (InVS), Brest University Hospital and Rennes network on all causes of death.
  3. Pharmaco-epidemiology

In clinical terms, the registry offers an opportunity to do an inventory of all current practices (diagnosis, therapies and the subsidiaries) and propose in this manner the best management of stroke. This strategy is in line with the pilot programs deployed by the French High Health Authority (HAS) for improvement of quality and safety of the health care. The bleeding risk associated with anticoagulants and anti-platelet agents in people of Brest as well as that of Dijon and Lille (in collaboration with their respective registry) will be analyzed.

This study has gained a particular characteristic since 2012 with emerging new oral anticoagulants (OAC) which have shown less associated bleeding risks compared with vitamin K antagonists (randomized controlled trials).

•In terms of clinical research :

  1. Study the impacted consequences of stroke by socio-economic characteristics of the territories in the Pays de Brest
  2. Identify short and long term clinical predictors of mortality in patients who have had a hemorrhagic stroke.
  3. To identify clinical predictors of mortality in the short and long-term patients with ischemic stroke.
  4. To identify genetic predictors of mortality and long-term recurrence of patients with ischemic stroke
  5. Identify stroke identification algorithm from existing databases
03

Conditions studied

  • Cerebral (CVAs)
  • Ischemic Cerebrovascular Accident
  • Stroke
  • Brain Ischemia
  • Brain Hemorrhage
  • Ischemic Stroke
  • Hemorrhagic Stroke
  • Cerebrovascular Disorders
  • Transient Ischemic Attack (TIA)
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Diagnostic validated for one of the following pathologies:

  • Ischemic stroke,
  • Non-traumatic intracranial hematoma
  • Cerebral venous thrombosis Diagnostic after December 31, 2007 Age > 15 years on the date of the diagnostic Patient domiciled at the time of the diagnostic in one of the 79 communes defined beforehand

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnostic validated for one of the following pathologies:
  • Ischemic stroke,
  • Non-traumatic intracranial hematoma
  • Cerebral venous thrombosis Diagnostic after December 31, 2007 Age > 15 years on the date of the diagnostic Patient domiciled at the time of the diagnostic in one of the 79 communes defined beforehand

Exclusion criteria

Exclusion Criteria:

  • Age ≤ 15 years
  • Validated diagnosis (see below, § 4.2.2) of aneurysmal subarachnoid hemorrhage cerebrovascular
  • Diagnosis made before 1 January 2008
  • Unconfirmed diagnosis
  • Patient domiciled outside the previously defined area of residence
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Type of stroke (ischemic or haemorrhagic)

    The type of stroke ischemic or haemorrhagic will be collected from physician diagnostic

    Time frame: Inclusion

Secondary outcomes

  1. Patient outcome

    Patient outcome (mortality) wanted by mail from towns of birth

    Time frame: Every year after the inclusion during 10 years

07

Study locations

1 of 1 sites recruiting
  • CHRU de Brest
    Brest, 29200, France
    Recruiting
    • Serge TIMSIT · Contactserge.timsit@chu-brest.fr · +33298347620
    • Francois ROUHART · Sub investigator
    • Irina VIAKHIREVA · Sub investigator
    • François Mathias MERRIEN · Sub investigator
    • Philippe GOAS · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2008 to primary completion in Aug 2016, 103 months.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's 103 months is above that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2016
First posted
Sep 14, 2016
StartActual
Jan 2008
Primary completionActual
Aug 2016
CompletionEst.
Dec 2026
Last update
May 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02900521
Collaborators
Santé publique France-InVS (Institut National de Veille sanitaire), Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Sep 14, 2016
Start date
Jan 2008
Primary completion
Aug 2016
Completion
Dec 2026 (estimated)
Last update
May 26, 2023

Study contacts

Serge TIMSIT
Contact
serge.timsit@chu-brest.fr
+33298347620
Serge TIMSIT
principal investigator · CHRU La Cavale Blanche - BREST - FRANCE

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion